Deconstructing tumor heterogeneity: the stromal perspective
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
// Renee E. Vickman 1 , * , Douglas V. Faget 2 , * , Philip Beachy 3 , David Beebe 4 , Neil A. Bhowmick 5 , Edna Cukierman 6 , Wu-Min Deng 7 , James G. Granneman 8 , Jeffrey Hildesheim 9 , Raghu Kalluri 10 , Ken S. Lau 11 , Ernst Lengyel 12 , Joakim Lundeberg 13 , Jorge Moscat 14 , Peter S. Nelson 15 , Kristian Pietras 16 , Katerina Politi 17 , Ellen Puré 18 , Ruth Scherz-Shouval 19 , Mara H. Sherman 20 , David Tuveson 21 , Ashani T. Weeraratna 22 , Richard M. White 23 , Melissa H. Wong 20 , Elisa C. Woodhouse 9 , Ying Zheng 24 , Simon W. Hayward 1 , # and Sheila A. Stewart 2 , # 1 Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA 2 Department of Cell Biology and Physiology, Washington University in St. Louis, St. Louis, MO, USA 3 Department of Developmental Biology, Stanford University School of Medicine, Stanford, CA, USA 4 Department of Biomedical Engineering, University of Wisconsin – Madison, Madison, WI, USA 5 Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA 6 Department of Cancer Biology, Marvin and Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA 7 Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, LA, USA 8 Department of Molecular Medicine and Genetics, Wayne State University, Detroit, MI, USA 9 National Cancer Institute, Bethesda, MD, USA 10 Department of Cancer Biology, MD Anderson Cancer Center, Houston, TX, USA 11 Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN, USA 12 Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL, USA 13 SciLifeLab, Department of Gene Technology, KTH Royal Institute of Technology, Stockholm, Sweden 14 Weill Cornell Medicine, Rockefeller University Campus, New York, NY, USA 15 Department of Medicine, University of Washington, Seattle, WA, USA 16 Department of Laboratory Medicine, Lund University, Lund, Sweden 17 Department of Pathology, Yale University School of Medicine, New Haven, CT, USA 18 Department of Biomedical Sciences, University of Pennsylvania, Philidelphia, PA, USA 19 Department of Biomolecular Sciences, The Weizmann Institute of Science, Rehovot, Israel 20 Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA 21 Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA 22 Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA 23 Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA 24 Department of Bioengineering, University of Washington, Seattle, WA, USA * These authors contributed equally to this work # Workshop co-chairs Correspondence to: Jeffrey Hildesheim, email: hildesheimj@mail.nih.gov Elisa C. Woodhouse, email: woodhousee@mail.nih.gov Keywords: tumor microenvironment; stromal heterogeneity; extracellular matrix; cellular plasticity; therapy resistance Received: August 19, 2020 Accepted: August 24, 2020 Published: October 06, 2020 Copyright: © 2020 Vickman et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Significant advances have been made towards understanding the role of immune cell-tumor interplay in either suppressing or promoting tumor growth, progression, and recurrence, however, the roles of additional stromal elements, cell types and/or cell states remain ill-defined. The overarching goal of this NCI-sponsored workshop was to highlight and integrate the critical functions of non-immune stromal components in regulating tumor heterogeneity and its impact on tumor initiation, progression, and resistance to therapy. The workshop explored the opposing roles of tumor supportive versus suppressive stroma and how cellular composition and function may be altered during disease progression. It also highlighted microenvironment-centered mechanisms dictating indolence or aggressiveness of early lesions and how spatial geography impacts stromal attributes and function. The prognostic and therapeutic implications as well as potential vulnerabilities within the heterogeneous tumor microenvironment were also discussed. These broad topics were included in this workshop as an effort to identify current challenges and knowledge gaps in the field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tensional homeostasis and the malignant phenotype
Paszek, M. J., Zahir, N., Johnson, K. R., Lakins, J. N., Rozenberg, G. I., Gefen, A., Reinhart-King, C. A., Margulies, S. S., Dembo, M., Boettiger, D., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.010 · Cited by 3,941 · cited 1×
“Stromal stiffness, for instance, can signal normal epithelial cells to adopt malignant phenotypes [49, 50], while dormant tumor cells have been suggested to resist chemotherapy by residing within the perivascular niche [51].”
BackgroundA framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863 · cited 5×
“The third, scarce CAF cluster was characterized by the expression of development-associated genes and were provisionally named developmental CAFs (dCAF). dCAFs show some overlapping gene expression with tumor epithelium, suggesting that dCAFs may originate from cancer cells that underwent EMT.”
BackgroundInfluentialSelf-citationEpidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170 · cited 1×
“Aggressive tumor phenotypes resulting from targeted therapy, such as small cell lung cancers and neuroendocrine prostate tumors following EGFRand AR-targeted inhibition [7, 8], respectively, prompted the community to conclude that narrow tumor cell and mutational status-centric approaches alone are unlikely to succeed.”
BackgroundInfluentialDistinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
Öhlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M., Corbo, V., Oni, T. E., Hearn, S. A., Lee, E. J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162024 · Cited by 2,590
Self-citationElyada, E., Bolisetty, M., Laise, P., Flynn, W. F., Courtois, E. T., Burkhart, R. A., Teinor, J. A., Belleau, P., Biffi, G., Lucito, M. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0094 · Cited by 2,241
Self-citationDeep profiling of mouse splenic architecture with CODEX multiplexed imaging
Goltsev, Y., Samusik, N., Kennedy-Darling, J., Bhate, S., Hale, M., Vazquez, G., Black, S., & Nolan, G. P. (2018) · Cell · doi:10.1016/j.cell.2018.07.010 · Cited by 1,501 · cited 1×
“Despite recent technological advances, such as imaging mass cytometry and co-detection by indexing (CODEX) [52], histological analyses remain limited due to reliance on pre-existing antibodies.”
BackgroundTransparent Adult Zebrafish as a Tool for In Vivo Transplantation Analysis
White, R. M., Sessa, A., Burke, C., Bowman, T., LeBlanc, J., Ceol, C., Bourque, C., Dovey, M., Goessling, W., Burns, C. E., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.002 · Cited by 1,408
Self-citationMechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383 · cited 1×
“However, only a subset of patients benefit from immunotherapies and little is known about the contribution of non-immune stromal cell types and extracellular matrix components to these processes, and even less is known about how these stromal functions and interactions differ throughout each stage of disease progressi…”
BackgroundBiffi, G., Oni, T. E., Spielman, B., Hao, Y., Elyada, E., Park, Y., Preall, J., & Tuveson, D. A. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0710 · Cited by 1,360
Self-citationMultimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma
Ji, A. L., Rubin, A. J., Thrane, K., Jiang, S., Reynolds, D. L., Meyers, R. M., Guo, M. G., George, B. M., Mollbrink, A., Bergenstråhle, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.039 · Cited by 1,117 · cited 1×
“The spatial interaction between stroma and various tumor subpopulations at the leading edge has recently been investigated in squamous cell carcinoma [54].”
BackgroundSelf-citation
Cited by
Spatially confined sub-tumor microenvironments in pancreatic cancer
Grünwald, B. T., Devisme, A., Andrieux, G., Vyas, F., Aliar, K., McCloskey, C. W., Macklin, A., Jang, G. H., Denroche, R., Romero, J. M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.022 · Cited by 433
Activated fibroblasts in cancer: Perspectives and challenges
Caligiuri, G., & Tuveson, D. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.015 · Cited by 424
Self-citationMhaidly, R., & Mechta‐Grigoriou, F. (2021) · Immunological Reviews · doi:10.1111/imr.12978 · Cited by 231
Cancer-Associated Fibroblasts: Tumorigenicity and Targeting for Cancer Therapy
Glabman, R. A., Choyke, P. L., & Sato, N. (2022) · Cancers · doi:10.3390/cancers14163906 · Cited by 254
Davis, L., Recktenwald, M., Hutt, E., Fuller, S., Briggs, M., Goel, A., & Daringer, N. (2022) · Cancers · doi:10.3390/cancers14051259 · Cited by 83
Metadata
- Authors
- Vickman, R. E., Faget, D. V., Beachy, P., Beebe, D., Bhowmick, N. A., Cukierman, E., Deng, W.-M., Granneman, J. G., Hildesheim, J., Kalluri, R., Lau, K. S., Lengyel, E., Lundeberg, J., Moscat, J., Nelson, P. S., Pietras, K., Politi, K., Puré, E., Scherz-Shouval, R., Sherman, M. H., Tuveson, D., Weeraratna, A. T., White, R. M., Wong, M. H., Woodhouse, E. C., Zheng, Y., Hayward, S. W., & Stewart, S. A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2020-10-06
- Volume
- 11
- Issue
- 40
- Pages
- 3621-3632
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W3092208609
- Cited by
- 42
- References
- 23
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.